After four years of follow-up, final pre-specified overall survival analysis from the pivotal phase III CLEAR/KEYNOTE-581 trial showed that Keytruda plus Lenvima maintained a clinically meaningful OS benefit versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma, reducing the risk of death by 21%.
Preliminary results from eight patients in the phase I portion of the Acclaim-1 clinical study evaluating Reqorsa immunogene therapy (quaratusugene ozeplasmid) with Tagrisso (osimertinib) in patients with advanced, EGFR mutant non-small cell lung cancer whose disease progressed after Tagrisso showed that Reqorsa was generally well tolerated, as there were no dose limiting toxicities. Promising efficacy results were also observed.
A study by Fox Chase Cancer Center researchers found that as many as 23% of cystic renal masses may carry high grade, or aggressive, disease.
American Society of Clinical Oncology featured studies on surgical techniques, immunotherapy, weight loss, racial disparities, and international collaboration ahead of the 2023 ASCO annual meeting. The research will be presented at the conference.
A commentary published in the Journal of the National Cancer Institute addresses the issue of cancer equity for people who have been impacted by mass incarceration.
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening, and may now be diagnosed at later stages, placing an increased burden on an already strained healthcare system, according to a new research article published in the Journal of the American College of Surgeons.
Researchers from Rice University and Baylor College of Medicine have identified a “glyco-immune” checkpoint inhibitor that could help treat bone cancer metastasis for breast cancer survivors.
Virginia Tech researchers with the Fralin Biomedical Research Institute at VTC have joined a Children’s National Hospital effort to treat deadly brain tumors with ultrahigh frequency sound waves.
A large-scale retrospective analysis by researchers with the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestry.
A study, led by researchers at the UCLA Jonsson Comprehensive Cancer Center, found that targeting a metabolic process in people with a specific genetic mutation could help treat glioblastoma.
